 I-Mab IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, and MorphoSys AG FSE: MOR; Prime Standard Segment, MDAX TecDAX; NASDAQ: MOR, today jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys investigational human CD38 antibody TJ202MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma rr MM. Under a licensing agreement with MorphoSys, I-Mab has exclusive rights for development and commercialization of TJ202MOR202 in mainland China, Taiwan, Hong Kong and Macao. 